hBCMA-BBζ CAR T cells

hBCMA-BBζ CAR T cells are a humanized chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antigen (BCMA), primarily developed for the treatment of multiple myeloma. The therapeutic construct utilizes a humanized single-chain variable fragment (scFv) for antigen specificity, coupled with a 4-1BB (CD137) costimulatory domain and a CD3ζ signaling domain. This second-generation CAR configuration is designed to promote superior T-cell persistence and metabolic fitness compared to CD28-based alternatives. Preclinical research indicates that the in vivo expansion and anti-tumor efficacy of these cells are significantly supported by endogenous CD28 signaling, which regulates mitochondrial oxidative phosphorylation and redox balance within the bone marrow microenvironment. The therapy is being investigated to overcome resistance mechanisms in multiple myeloma and to evaluate the potential of transient co-stimulation blockade to mitigate cytokine-related toxicities.

Other names

hBCMABBζ CAR T cellshumanized BCMA-targeted 4-1BB-CD3ζ CAR T cells